Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance

Antiviral Research

Volumn 56, Issue 2, 2002, Pages 129-142

  Loemba, Hugues ^a   Brenner, Bluma ^a   Parniak, Michael A ^a   Ma'ayan, Shlomo ^c   Spira, Bonnie ^a   Moisi, Daniela ^a   Oliveira, Maureen ^a   Detorio, Mervi ^a   Essex, Max ^b,d   Wainberg, Mark A ^a  

^a MCGILL UNIVERSITY   (Canada)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d Botswana Harvard Laboratory   (Botswana)

Author keywords

Antiretroviral drugs; Cytotoxic T lymphocyte (CTL); Polymorphisms

Indexed keywords

DELAVIRDINE; EFAVIRENZ; EPITOPE; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; VIRUS ENVELOPE PROTEIN; ZIDOVUDINE;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ARTICLE; BOTSWANA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ETHIOPIA; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; LYMPHOCYTE FUNCTION; MUTATION; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; BASE SEQUENCE; BOTSWANA; CELLS, CULTURED; DNA, VIRAL; DRUG RESISTANCE, VIRAL; EPITOPES, T-LYMPHOCYTE; ETHIOPIA; GENES, ENV; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; MOLECULAR SEQUENCE DATA; MUTAGENESIS; PHYLOGENY; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036843080     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(02)00100-6     Document Type: Article

References (41)

1. Boulerice F., Bour S., Geleziunas R., Lvovich A., Wainberg M.A. High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells. J. Virol. 64:1990;1745-1755.
2. Brander C., Goulder P.J.R. The evolving field of HIV CTL epitope mapping: new approaches to the identification of novel epitopes. Brander C., Korber B.T.M., Walker B.D., Koup R.A., Moore J., Haynes B., Meyers G., HIV Molecular Immunology Database. 2000;Los Alamos National Laboratory, Los Alamos, New Mexico.
3. Burke D.S., McCutchan F.E. Global distribution of human immunodeficiency virus-1 clades. Vincent T., De Vital J., Hellman S., Rosenberg S.A., AIDS: Biology, Diagnosis, Treatment and Prevention. 1997;119-126 Lippincott-Raven, Philadelphia.
4. gag protein. J. Virol. 67:1993;694-702.
5. Cao H., Kanki P., Sankale J.L., Dieng-Sarr A., Mazzara G.P., Kalams S.A., Korber B., Mboup S., Walker B.D. Cytotoxic T-lymphocytes cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development. J. Virol. 71:1997;8615-8623.
6. Culmann-Penciolelli B., Lamhamedi-Cherradi S., Couillin I., Guegan N., Levy J.P., Guillet J.G., Gomard E. Identification of multi-restricted immunodominant regions recognized by cytolytic T lymphocytes in the human immunodeficiency virus type 1 Nef protein. J. Virol. 68:1994;7336-7343.
7. Dalod M., Harzic M., Pellegrin I., Dumon B., Hoen B., Sereni D., Deschemin J.C., Levy J.P., Venet A., Gomard E. Evolution of cytotoxic T lymphocytes responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. J. Infect. Dis. 178:1998;61-69.
8. Day C.L., Shea A.K., Altfeld M.A., Olson D.P., Buchbinder S.P., Hecht F.M., Rosenberg E.S., Walker B.D., Kalams S.A. Relative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA alleles. J. Virol. 75:2001;6279-6291.
9. Del Val M., Schlicht H.J., Ruppert T., Reddehase M.J., Koszinowski U.H. Efficient processing of an antigenic sequence for presentation by MHC class 1 molecules depends on its neighboring residues in the protein. Cell. 66:1991;1145-1153.
10. Delwart E.L., Shpaer E.G., Louwagie J., McCutchan F.E., Grez M., Rubsamen-Waigmann H., Mullins J.I. Genetic relationships determined by DNA heteroduplex mobility assay: analysis of HIV-1 Env genes. Science. 262:1993;1257-1261.
11. Dietrich U., Grez M., von Briesen H., Panhans B., Geissendorfer M., Kuhnel H., Maniar J., Mahambre G., Becker M.L.B., Rubsamen-Waigmann H. HIV-1 strains from India are highly divergent from prototypic African and US/European strains, but are linked to a South African isolate. AIDS. 7:1993;23-27.
12. Dupuis M., Kundu S.K., Merigan T.C. Characterization of HLA-A 0201-restricted cytotoxic T cell epitopes in conserved regions of the HIV type 1 gp160 protein. J. Immunol. 155:1995;2232-2239.
13. Durant J., Clevenbergh P., Halfon P., Delgiudice P., Porsin S., Simonet P., Montagne N., Boucher C.A.B., Schapiro J.M., Dellamonica P. Drug resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet. 353:1999;2195-2199.
14. Essex M. Human immunodeficiency viruses in the developing world. Adv. Virus Res. 53:1999;71-88.
15. Gao Q., Gu Z., Parniak M.A., Li X., Wainberg M.A. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine. J. Virol. 66:1992;12-19.
16. Goulder P.J., Phillips R.E., Colbert R.A., McAdam S., Ogg G., Nowak M.A., Giangrande P., Luzzi G., Morgan B., Edwards A., McMichael A.J., Rowland J.S. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nature Med. 3:1997;212-217.
17. Gray C.M., Lawrence J., Schapiro J.M., Altman J.D., Winters M.A., Crompton M., Loi M., Kundu S.K., Davis M.M., Merigan T.C. Frequency of class 1 HLA-restricted anti-HIV CD8+T cells in individuals receiving highly active antiretroviral therapy (HAART). J. Immunol. 162:1999;1780-1789.
18. Haas G., Samri A., Gomard E., Hosmalin A., Duntze J., Bouley J.M., Ihlenfeldt H.G., Katlama C., Autran B. Cytotoxic T-cell responses to HIV-1 reverse transcriptase, integrase and protease. AIDS. 12:1998;1427-1436.
19. Harrer E., Harrer T., Barbosa P., Feinberg M., Johnson R.P., Buchbinder S., Walker B.D. Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor. J. Infect. Dis. 173:1996;476-479.
20. Joint United Nations Programme on HIV/AIDS. June 2000. AIDS epidemic update.
21. Kelleher A.D., Long C., Holmes E.C., Allen R.L., Wilson J., Conlon C., Workman C., Shaunak S., Olson K., Goulder P., Brander C., Ogg G., Sullivan J.S., Dyer W., Jones I., McMichael A.J., Rowland-Jones S., Phillips R.E. Clustered mutations in HIV-1 Gag are consistently required for escape from HLA-B27-restricted CTL responses. J. Exp. Med. 193:2001;375-386.
22. Kohlstaedt L.A., Wang J., Friedman J.M., Rice P.A., Steitz T.A. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 256:1992;1783-1790.
23. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., Farthing C., Ho D.D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:1994;4650-4655.
24. Loemba H., Brenner B., Parniak M.A., Ma'ayan S., Spira B., Moisi D., Oliveira M., Detorio M., Wainberg M.A. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob. Agents Chemother. 46:2002;2087-2094.
25. McMichael A.J., Rowland-Jones S.L. Cellular immune responses to HIV. Nature. 410:2001;980-987.
26. Myers, J., Gamberg, J., Bowmer, M.I., Grant, M., 2001. Immunological recognition of drug resistant HIV. Tenth Annual Canadian Conference on HIV/AIDS Research, CAHR, Toronto, Canada, Abstract 106.
27. Nabel G.J. Challenges and opportunities for development of an AIDS vaccine. Nature. 410:2001;1002-1007.
28. Ossendorp F., Eggers M., Neisig A., Ruppert T., Groettrup M., Sijts A., Mengede E., Kloetzel P.M., Neefjes J., Koszinowski U., Melief C. A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Immunity. 5:1996;115-124.
29. Palella F.J. Jr, Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl. J. Med. 338:1998;853-860.
30. Pantaleo G. How immune-based interventions can change HIV therapy. Nature Med. 3:1997;483-490.
31. Richman D.D. HIV chemotherapy. Nature. 410:2001;995-1001.
32. Ridge J.P., Di Rosa F., Matzinger P.A. A conditioned dendritic cell can be a temporal bridge between a CD4+T-helper and a T-killer cell. Nature. 393:1998;474-478.
33. Rowland-Jones S.L., Dong T., Fowke K.R., Kimani J., Krausa P., Newell H., Blanchard T., Ariyoshi K., Oyugi J., Ngugi E., Bwayo J., MacDonald K.S., McMichael A.J., Plummer F.A. Cytotoxic T-cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 102:1998;1758-1765.
34. Salomon H., Belmonte A., Nguyen K., Gu Z., Gelfand M., Wainberg M.A. Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1. J. Clin. Microbiol. 32:1994;2000-2002.
35. Samri A., Haas G., Duntze J., Bouley J.M., Calvez V., Katlama C., Autran B. Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells. J. Virol. 74:2000;9306-9312.
36. Schinazi R.F., Larder B.A., Mellors J.W. Mutations in retroviral genes associated with drug resistance. Int. Antiviral News. 4:1996;95-107.
37. Schmitt M., Harrer E., Goldwich A., Baurele M., Graedner I., Kalden J.R., Harrer T. Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes. AIDS. 14:2000;653-658.
38. van der Burg S.H., Klein M.R., van de Velde C.J.H., Kast W.M., Miedema F., Melief J.M. Induction of a primary human cytotoxic T-lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptase. AIDS. 9:1995;121-127.
39. Wainberg M.A. HIV resistance to antagonists of viral reverse transcriptase. Dalgleish A., Weiss R., AIDS and the New Viruses. Second Ed. 1999;223-249 Academic Press, London.
40. Wainberg M.A., Cameron D.W. HIV resistance to antiretroviral drugs: public health implications. Drug Resist. Updates. 1:1998;104-108.
41. Walker B.D., Flexner C., Paradis T.J., Fuller T.C., Hirsch M.S., Schooley R.T., Moss B. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science. 240:1998;64-66.